Neoadjuvant botensilimab and balstilimab in colorectal cancer

Smitha Krishnamurthi, Gastrointestinal medical oncologist at Cleveland Clinic, shared on X:

“Neoadjuvant botensilimab (1 dose) and balstilimab (4 doses) resulted in pathologic complete response in 5/9 patients with pMMR colorectal cancer!

Early results but super impressive.”